The move comes after tests that the company said were promising. For the past several years, GlaxoSmithKline has conducted tests of its vaccine on almost 15,500 children in seven African countries. The company reports that 18 months after vaccination, there was a 27 percent reduction in malaria cases in infants aged 6-12 weeks and a 46 percent reduction in children aged 5-17 months.
Now it’s applying to the European Medicines Agency to start marketing the vaccine. GlaxoSmithKline’s research was supported by the Bill and Melinda Gates Foundation and the company says it will make the vaccine affordable for poorer nations.Ninety percent of the world’s malaria cases are in the poorer regions of sub-Saharan Africa where the vaccine was tested. Globally, malaria kills 800,000 people a year. It’s also a major hazard for adventure travelers. While antimalarial pills are generally effective, they can have serious side effects. A vaccination would go a long way to easing the burden on people who choose to visit the tropics.
Approval for the vaccine could come in 2014. Unfortunately, the percentages the company is quoting do not indicate that it will be as effective as many of the vaccines we are used to. Other measures are still needed like the education of the public of the dangers of standing water and the need to use mosquito netting. More innovative methods for fighting the disease like infecting them with bacteria are also being studied.
Hopefully GlaxoSmithKline’s vaccine will be just the first generation of a series of improving vaccines that will one day relieve the world of a dangerous disease.